Virion Therapeutics
Biotechnology, 7 CRK BND Ct, Newark, Delaware, 19711, United States, 11-50 Employees
Phone Number: +18*********
Who is VIRION THERAPEUTICS
At Virion Therapeutics, We Believe a Future Free of Cancer and Chronic Infectious Diseases Is Within Reach Driven by science, our mission is to revolutionize the immunotherapy treatment l...
Read More
-
Headquarters: 7 CRK BND Ct, Newark, Delaware, 19711, United States
-
Date Founded: 2018
-
Employees: 11-50
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
Does something look wrong? Fix it. | View contact records from VIRION THERAPEUTICS
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Virion Therapeutics
Answer: Virion Therapeutics's headquarters are located at 7 CRK BND Ct, Newark, Delaware, 19711, United States
Answer: Virion Therapeutics's phone number is +18*********
Answer: Virion Therapeutics's official website is https://viriontx.com
Answer: Virion Therapeutics's revenue is Under $1 Million
Answer: Virion Therapeutics's SIC: 8731
Answer: Virion Therapeutics has 11-50 employees
Answer: Virion Therapeutics is in Biotechnology
Answer: Virion Therapeutics contact info: Phone number: +18********* Website: https://viriontx.com
Answer: At Virion Therapeutics, We Believe a Future Free of Cancer and Chronic Infectious Diseases Is Within Reach Driven by science, our mission is to revolutionize the immunotherapy treatment landscape, focusing on the development of novel, adaptable, and accessible CD8+ T cell-based technologies. Our transformative platform is first in its class, offering a unique methodology that combines innovative and established approaches to elicit a superior CD8+ T cell response. Novel genetically encoded checkpoint modifiers are delivered alongside optimized target-specific antigens via an immunogenic and adaptable viral vector platform that promotes potent, prolonged, and broad CD8+ T cell responses. With potential applications across a range of cancers and chronic infectious diseases, our proprietary technology provides us with a robust pipeline. Our lead product, VRON-0200, is under investigation as a potential functional cure for the treatment of chronic hepatitis B virus (HBV) a first-in-human clinical study is planned to initiate in late 2022. Founded in 2018 to advance technology licensed from The Wistar Institute, we have assembled a world-class management team and an industry-leading global Board of Directors, with proven experience in the biotechnology sector, as well as extensive preclinical and clinical expertise in antiviral, vaccine, oncology, and immuno-oncology.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month